Focal adhesion kinase, a novel target for cancer therapy

23 1 2011 1 Chinese Bulletin of Life Sciences Vol. 23, No. 1 Jan., 2011 (1 ; 2 210093) (focal adhesion kinase, FAK) FAK FAK FAK FAK R34 R730.54 A Focal adhesion kinase, a novel target for cancer therapy ZHANG Wen-Jing 1, HUANG Qi-Lai 1 *, HUA Zi-Chun 1, 2 * (1Faculty of Chinese Medicine and Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China; 2The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China) Abstract: Focal adhesion kinase (FAK), a cytoplasmic non-receptor protein tyrosine kinase, serves as both a molecular scaffold and a mediator participating in multiple signal transduction pathways. FAK is involved in tumor cell survival, proliferation, migration and metastasis. Currently, FAK has been regarded as a potential target for cancer therapy. This review is to summarize the relationship between FAK and tumor progression, and to discuss the strategies targeting FAK for cancer treatment. Key words: focal adhesion kinase; antitumor; treatment (focal adhesion kinase, FAK) FAK 1992 v-src FAK FAK FAK [1] FAK FAK FAK 2010-07-20 2010-08-23 (071/2009/A3 091/ 2009/A) FAK E-mail: zchua@nju.edu.cn ( ) E-mail: qlhuang@must.edu.mo

8 FAT X FAK 8q24 FAK 15 125 k FAK (paxillin) (talin) 90% LD2 LD4 FAT [2] FAK Src SH2 SH3 N- FERM [7-10] 965 1012 (PR1 PR2 PR3) C- (focal adhesion target FAT) 6 Y397 Y407 Y576 Y577 Y861 Y925( 1) FAT 1 3 FAT C FAK FRNK FAK FRNK [11] FRNK FRNK FAK [ 1 2 F A K ] FRNK MAPK FAK FAK FIP200 [13] FAK [14] FAK SOCS FAK FERM 300 FAK Y397 4.1 FERM F A K E GF R Y397 PDGFR FAK FERM β FAK Y397 FAK FERM Src SH2 Src FERM FAK S r c [15] FERM FAK Tyr576/577 FAK FERM FAK paxillin p130cas FAK-Src Src FAK paxillin p130cas Crk FERM p53 SH2 G FAK Rac-1 cdc42 JNK [16] FERM F1 p53 F2 Src Tyr407 p53 F3 Mdm-2 Tyr861 Tyr925 p53 [3] N- PR1 SH2 ( Grb2) [17] SH3 Src Grb2 SH2 SH3 C PR2 PR3 FAK SH3 Ras SOS p 13 0C as Ras FAK Graf(Rho-A GTPase Ras/MAPK Y397 FAK) ASAP1(ARF-GAP SH2 Shc SH3 ANK PH ) [4-6] FAK PLCγ PI3K 85 Grb7 [18-20] C FAT FAT FAK Src FAK 15.5 k FAT FAK

9 [21] FAK FAK FAK FAK [34] FAK FAK FAK FAK FAK FAK FAK [22] FAK FAK FAK FAK FIP200 Ueda [35] FAK ERK [23,24] PKC/PI3K [25] Cyclin D1 Cyclin D3 mrna Pyk2 FIP200 FAK p130 CAS PI3K FAK [26] FAK p130 CAS p130 CAS FIP200 FAK FAK FIP200 FAK [27,28] Y397 FAK FAK FIP200 FAK [29] FAK F AK FIP200 FAK Pyk2 FAK Pyk2 FIP200 FAK FRNK FAK [30,31] [36] FAK FAK C- FRNK [37] FAK-Src FAK FAK -/- FRNK FAK FAK FRNK [2] FRNK FAK FRNK v-src [32] FAK NIH 3T3 FRNK FAK C D 2 B16-F10 FAK Y397 FRNK 50% [33] FAK FRNK (CD2-FAK) MDCK FAK FRNK MTLn3

1 0 FAK Y397 FAK Pyk2 FRNK 60% FRNK H460 FAT FAK U251MG FAK PF-562271 [38] FAT FAK LN-401 TAE226 ATP [39] [44] FAT FAK FAK F A K FAK FAT TAE226 - [45] TAE226 30 [4 0] MiaPaCa-2 FAK TAE226 RNA (sirna) FAK [42] AU-565 HA FRNK AU- FAK 565 FAK FAK ( sirna) FAK AU-565 FRNK FAT FIP200 FAK sirna FAK FRNK FAK FAK B16F10 FAK FAK FAK sirna FRNK sirna FAK DNA [1] Hao H, Naomoto Y, Bao X, et al. Focal adhesion kinase as FAK PF-573228 PF-562271 NVP-226 ATP PF-573228 TAE226 TAE226 [41] FAK FAK FAK AU-565 sirna FAK [ 43 ] [2] potential target for cancer therapy (Review). Oncol Rep, 2009, 22 (5): 973-9 van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol, 2007, 73 (5): 597-609 FAK [3] Lim ST, Mikolon D, Stupack DG, et al. FERM control of FAK function: implications for cancer therapy. Cell Cycle, 2008, 7 (15): 2306-14 [4] Harte MT, Hildebrand JD, Burnham MR, et al. p130cas, a FAK paxillin substrate associated with v-src and v-crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem, FAK 1996, 271 (23): 13649-55 [5] Liu Y, Loijens JC, Martin KH, et al. The association of FERM PF-562271 ASAP1, an ADP ribosylation factor-gtpase activating

1 1 protein, with focal adhesion kinase contributes to the process of focal adhesion assembly. Mol Biol Cell, 2002, 13 (6): 2147-56 [6] Taylor JM, Hildebrand JD, Mack CP, et al. Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. J Biol Chem, 1998, 273 (14): 8063-70 [7] Brown MC, Perrotta JA, Turner CE. Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. J Cell Biol, 1996, 135 (4): 1109-23 [8] Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene, 2001, 20 (44): 6459-72 [9] Schaller MD, Otey CA, Hildebrand JD, et al. Focal adhesion kinase and paxillin bind to peptides mimicking β integrin cytoplasmic domains. J Cell Biol, 1995, 130 (5): 1181-7 [10] Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol, 2000, 2 (12): E231-6 [11] Taylor JM, Mack CP, Nolan K, et al. Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol Cell Biol, 2001, 21 (5): 1565-72 [12] Nolan K, Lacoste J, Parsons JT. Regulated expression of focal adhesion kinase-related nonkinase, the autonomously expressed C-terminal domain of focal adhesion kinase. Mol Cell Biol, 1999, 19 (9): 6120-9 [13] Abbi S, Ueda H, Zheng C, et al. Regulation of focal adhesion kinase by a novel protein inhibitor FIP200. Mol Biol Cell, 2002, 13 (9): 3178-91 [14] Liu E, Cote JF, Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J, 2003, 22 (19): 5036-46 [15] Owen JD, Ruest PJ, Fry DW, et al. Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol, 1999, 19 (7): 4806-18 [16] Cho SY, Klemke RL. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol, 2000, 149 (1): 223-36 [17] Cary LA, Guan JL. Focal adhesion kinase in integrin-mediated signaling. Front Biosci, 1999, 4: D102-13 [18] Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA, 1994, 91 (21): 10148-52 [19] Chen HC, Appeddu PA, Isoda H, et al. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem, 1996, 271 (42): 26329-34 [20] Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem, 1999, 274 (34): 24425-30 [21] Hecker TP, Grammer JR, Gillespie GY, et al. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res, 2002, 62 (9): 2699-707 [22] Chatzizacharias NA, Kouraklis GP, Theocharis SE. Focal adhesion kinase: a promising target for anticancer therapy. Expert Opin Ther Targets, 2007, 11 (10): 1315-28 [23] Zhao J, Pestell R, Guan JL. Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell, 2001, 12 (12): 4066-77 [24] Zhao JH, Reiske H, Guan JL. Regulation of the cell cycle by focal adhesion kinase. J Cell Biol, 1998, 143 (7): 1997-2008 [25] Yamamoto D, Sonoda Y, Hasegawa M, et al. FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell Signal, 2003, 15 (6): 575-83 [26] Almeida EA, Ilic D, Han Q, et al. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-jun NH(2)- terminal kinase. J Cell Biol, 2000, 149 (3): 741-54 [27] Aronsohn MS, Brown HM, Hauptman G, et al. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope, 2003, 113 (11): 1944-8 [28] Moon HS, Park WI, Choi EA, et al. The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer, 2003, 13 (5): 640-6 [29] Withers BE, Hanks SK, Fry DW. Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125fak, in tumor and nontransformed cells. Cancer Biochem Biophys, 1996, 15 (3): 127-39 [30] Chan KT, Cortesio CL, Huttenlocher A. FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion. J Cell Biol, 2009, 185 (2): 357-70 [31] Provenzano PP, Keely PJ. The role of focal adhesion kinase in tumor initiation and progression. Cell Adh Migr, 2009, 3 (4): 347-50 [32] Frisch SM, Vuori K, Ruoslahti E, et al. Control of adhesiondependent cell survival by focal adhesion kinase. J Cell Biol, 1996, 134 (3): 793-9 [33] Chan PY, Kanner SB, Whitney G, et al. A transmembraneanchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125fak. J Biol Chem, 1994, 269 (32): 20567-74 [34] Ilic D, Furuta Y, Kanazawa S, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature, 1995, 377 (6549): 539-44 [35] Ueda H, Abbi S, Zheng C, et al. Suppression of Pyk2 kinase and cellular activities by FIP200. J Cell Biol, 2000, 149 (2): 423-30 [36] Schaller MD. The focal adhesion kinase. J Endocrinol, 1996, 150 (1): 1-7 [37] Hauck CR, Hsia DA, Puente XS, et al. FRNK blocks v-srcstimulated invasion and experimental metastases without effects on cell motility or growth. EMBO J, 2002, 21 (23): 6289-302 [38] Wang D, Grammer JR, Cobbs CS, et al. p125 focal adhesion

1 2 kinase promotes malignant astrocytoma cell proliferation in vivo. J Cell Sci, 2000, 113 Pt 23: 4221-30 [39] Jones G, Machado J Jr, Merlo A. Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res, 2001, 61 (13): 4978-81 [40] Jones G, Machado J Jr, Tolnay M, et al. PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK). Cancer Res, 2001, 61 (15): 5688-91 [41] Huang YT, Lee LT, Lee PP, et al. Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability. Anticancer Res, 2005, 25 (3B): 2017-25 [42] Earley S, Plopper GE. Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells. Biochem Biophys Res Commun, 2006, 350 (2): 405-12 [43] Li S, Dong W, Zong Y, et al. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol Ther, 2007, 15 (3): 515-23 [44] Shi Q, Hjelmeland AB, Keir ST, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog, 2007, 46 (6): 488-96 [45] Liu TJ, LaFortune T, Honda T, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-i receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther, 2007, 6 (4): 1357-67